A major trial has provided more details about the risk of lung injury with low-dose methotrexate (MTX), and in particular for MTX-related pneumonitis. One of the largest studies ever of low-dose methotrexate use – involving 2,391 people randomised to receive the drug – showed a rate of severe pulmonary adverse events of 0.5%, with more ...
New details emerge on pulmonary injury with low-dose MTX
By Michael Woodhead
14 Oct 2020